Scribd Logo
Upload

Welcome to Scribd!

  • Abstrak Jurnal 6 Hadika

    Uploaded by

    Dr. Hadika Pramana, SpPD
    8 views1 page
    This study evaluated the long-term effectiveness of secukinumab (SCK) in treating axial spondyloarthritis (AxSpA) using a cohort of 39 patients from three Italian hospitals over 2 years. AxSpA is a chronic inflammatory disease affecting the spine and sacroiliac joints. The study found that both the BASDAI and ASDAS-CRP scores, which measure disease activity, significantly decreased over the observation period. By the end, 78.2% of patients remained on SCK treatment. There were no significant differences in retention rates between biologic-naive and anti-TNF failure patients. No adverse events were reported. The study concludes that SCK is an effective and safe long

    Original Description:

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This study evaluated the long-term effectiveness of secukinumab (SCK) in treating axial spondyloarthritis (AxSpA) using a cohort of 39 patients from three Italian hospitals over 2 years. AxSpA is a chronic inflammatory disease affecting the spine and sacroiliac joints. The study found that both the BASDAI and ASDAS-CRP scores, which measure disease activity, significantly decreased over the observation period. By the end, 78.2% of patients remained on SCK treatment. There were no significant differences in retention rates between biologic-naive and anti-TNF failure patients. No adverse events were reported. The study concludes that SCK is an effective and safe long

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    8 views1 page

    Abstrak Jurnal 6 Hadika

    Uploaded by

    Dr. Hadika Pramana, SpPD
    This study evaluated the long-term effectiveness of secukinumab (SCK) in treating axial spondyloarthritis (AxSpA) using a cohort of 39 patients from three Italian hospitals over 2 years. AxSpA is a chronic inflammatory disease affecting the spine and sacroiliac joints. The study found that both the BASDAI and ASDAS-CRP scores, which measure disease activity, significantly decreased over the observation period. By the end, 78.2% of patients remained on SCK treatment. There were no significant differences in retention rates between biologic-naive and anti-TNF failure patients. No adverse events were reported. The study concludes that SCK is an effective and safe long

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    Journal Reading

    Long-term effectiveness of secukinumab in patients with


    axial spondyloarthritis
    Gentileschi S, Rigante D, Sota J, Lopalco G,Giannotta M, Emmi G, et al
    Hindawi, Volume 50 Number 1 (2020)

    Axial Spondyoarthritis (AxSpA) is a chronic, autoinflammatory disease


    predominantly affecting the axial skeleton (sacroiliac joints and spine), and a term for
    types of inflammatory arthritis that primarily affect the spine and the sacroiliac (SI)
    joints that connect the lower spine to the pelvis, resulting in pain in the lower back,
    hips, and buttocks. AxSpA is divided into two groups : Non-radiographic axial
    spondyloarthritis (nr-axSpA) and Radiographic axial spondyloarthritis (ankylosing
    spondylitis).
    This Study used cohort from patient diagnosed with axSpA from ASAS
    criteria and undergoing secukinumab (SCK) treatment in three Italian referral centres
    (Siena, Bari, and Florence) which is included 39 patients . Laboratory and clinical
    evaluation was performed at baseline and every 3 months for the first year and In the
    second year of treatment, follow-up visits were performed every 6 months. Disease
    activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index
    (BASDAI) and the Ankylosing Spondylitis Disease Activity Score- (ASDAS-) CRP.
    The primary aim of the study was to evaluate SCK’s long-term efficacy in the
    management of axSpA manifestations.
    This study showed that the both BASDAI and ASDAS-CRP showed a
    statistically significant reduction in the observation period. At the end of the
    observation period, 7 out of 39 (17.94%), patients discontinued SCK due to lack of
    efficacy (n = 2), loss of efficacy (n = 3), or poor compliance (n = 2). Author got
    78.2% global drug retention rate at the end of the study period, without any
    significant differences between biologic-naive and anti-TNF-α-failure patients (p =
    0,619) or between subjects administered with different SCK dosages (p = 0,614).
    There is no statistically significant variation of ESR emerged between baseline and
    the follow-up assessments. And there is no adverse events were reported during the
    observation time.
    In conclusion, Author states that SCK has proved to have a remarkable drug
    retention rate and SCK has an effective and safe profile in the management of a real-
    life heterogeneous cohort of axSpA patients.

    Will be presented by Hadika Pramana


    On Monday, October 12th, 2020

    You might also like